openPR Logo
Press release

Biogenum Announces Favorable Safety Profile for Tau NonTangles™ in a Phase 1/2 Clinical Trial in Patients with Alzheimer’s Disease

12-05-2019 03:50 PM CET | Health & Medicine

Press release from: Biogenum

Tau NonTangles™ - small molecule for Alzheimer’s disease treatment is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias

Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced topline results from the company’s Phase 1/2 clinical study evaluating Tau NonTangles™ - small molecule for Alzheimer’s Disease treatment, its potent and selective phosphodiesterase inhibitor, in patients with mild-to-moderate Alzheimer’s disease maintained on stable medication (e.g., dopamine replacement therapies). The results will be presented at the 2020 Neurological Committee Annual Meeting being held in Singapore.
The primary objective of this Phase 1/2, randomized, double-blind, placebo-controlled, multiple ascending dose cohort study was to evaluate the safety and tolerability of Tau NonTangles™ - small molecule for Alzheimer’s disease treatment and to explore the potential for Tau NonTangles™ to treat both motor and non-motor symptoms associated with AD. Topline results demonstrate Tau NonTangles™ was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. The trial was conducted at the Center for Neurodegenerative Medical Research Unit.
“In this trial, once-daily Tau NonTangles™ for 7 days was shown to be safe and generally well tolerated across a broad range of doses from 1 mg to 80 mg in subjects currently maintained on dopamine replacement therapy,” commented Executive Vice President and Chief R&D Officer, Shin Hye-sung.
“Improvement in motor symptoms and reduction in motor complications were noted with Tau NonTangles™ treatment,” said Dr. Soung Myung-hee, Principal Investigator at the Center for Neurodegenerative Medical Research Unit, where the trial was conducted. “Several subjects with profound motor impairments improved dramatically while taking Tau NonTangles™ - small molecule for Alzheimer’s disease treatment, only to have these symptoms re-emerge after cessation of Tau NonTangles™ treatment.”
AboutTau NonTangles™ - Small molecule for Alzheimer’s disease treatment
The Tau NonTangles™ program discovers small molecules that are designed to inhibit the aggregation and seeding process of misfolded proteins and promote the disaggregation of already formed protein aggregates. Preclinical studies suggest reduction of pathological Tau aggregates leading to memory improvement.

Biogenum
WBC The Palace 2, 28 Centum 1-ro, U-dong, Haeundae-gu, Busan, South Korea
alice.lum@biogenum.com
Alice Lum Jin

About Biogenum
Biogenum is a privately held biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Alzheimer's disease, ALS and others. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Composed of proprietary chemistry and software, Biogenum delivers powerful answers using broadly installed instrument platforms. The company’s leadership team has decades of experience in drug discovery, translational strategy, corporate development and commercialization. Collectively, we have been instrumental in researching more than 10 drugs to be delivered in the market.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biogenum Announces Favorable Safety Profile for Tau NonTangles™ in a Phase 1/2 Clinical Trial in Patients with Alzheimer’s Disease here

News-ID: 1876307 • Views:

More Releases for Tau

LiDAR Cameras Market Analysis and Global Outlook 2021 to 2026 - Intel, Onion Tau …
The LiDAR Cameras Market research report provides detailed observation of several aspects, including the rate of growth, regional scope and recent developments by the primary market players. The report offers Porter’s Five Forces, PESTEL, and market analysis to provide a 360-degree research study on the global LiDAR Cameras market. The research study discusses about important market strategies, future plans, market share growth, and product portfolios of leading companies. The final
Histoplasmosis Treatment Market 2019 Analysis and Precise Outlook - Bristol Myer …
The report titled “Histoplasmosis Treatment Market” report will be very useful to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, SWOT analysis, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts. The Histoplasmosis Treatment market was
Acute Lymphoblastic Leukemia Market Size 2020-27 by Erytech Pharma, Spectrum Pha …
Global Acute Lymphoblastic Leukemia Market 2020 presents a broad investigation of Market size, drivers, patterns, openings, challenges, just as key Market sections. Further, it clarifies different definitions and characterization of the Acute Lymphoblastic Leukemia industry, applications, and chain structure. In continuation of this information, the Acute Lymphoblastic Leukemia report covers different showcasing techniques followed by key players and wholesalers. Likewise clarifies Acute Lymphoblastic Leukemia showcasing channels, potential purchasers, and advancement
Tau Protein Inhibitors Therapeutics - Pipeline Analysis 2018
Tau protein is found in abundance in neurons of the central nervous system. This protein is a product of microtubule-associated protein tau (MAPT) gene, that is located on chromosome 17. It is associated with pathologies of several nervous system disorders, such as dementia, Parkinson’s disease, and Alzheimer’s disease. Download the sample report @ https://www.pharmaproff.com/request-sample/1199 The main function of the protein is to stabilize microtubules. There are six isoforms of the protein
Inosine Pranobex Market Key Player Analysis By- Gedeon Richter, Mochida, Sanofi, …
Inosine pranobex (BAN; also known as inosine acedoben dimepranol (INN) or methisoprinol) an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex has no effect on viral particles itself. Instead, it acts as an immunostimulant, an analog of thymus hormones. It is most commonly used to treat the rare measles complication subacute
Global Motion Controllers Market 2016 Rta, Delta Tau, Advanced Micro Systems, Go …
A market study based on the " Motion Controllers market" across the globe, recently added to the repository of QY Market research, is titled ‘Global Motion Controllers Market 2016’. The research report analyzes the historical as well as present performance of the global Motion Controllers Market , and makes predictions on the future status of Motion Controllers market on the basis of this analysis. The report studies the market for Motion